Personalized Prostate Specific Antigen Testing Using Genetic Variants May Reduce Unnecessary Prostate Biopsies

被引:29
|
作者
Helfand, Brian T. [1 ]
Loeb, Stacy [3 ]
Hu, Qiaoyan [2 ]
Cooper, Phillip R. [2 ]
Roehl, Kimberly A. [2 ]
McGuire, Barry B. [2 ]
Baumann, Nikola A. [4 ]
Catalona, William J. [2 ]
机构
[1] Northshore Univ Healthcare Syst, Div Urol, Evanston, IL USA
[2] Northwestern Univ, Feinberg Sch Med, Dept Urol, Chicago, IL 60611 USA
[3] NYU, Dept Urol, New York, NY USA
[4] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA
来源
JOURNAL OF UROLOGY | 2013年 / 189卷 / 05期
关键词
prostatic neoplasms; polymorphism; single nucleotide; prostate-specific antigen; prostate; biopsy; CANCER MORTALITY; ASSOCIATION; RISK; PSA; POLYMORPHISMS; MULTIPLE; PROMOTER; MEN;
D O I
10.1016/j.juro.2012.12.023
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Recent studies have identified genetic variants associated with increased serum prostate specific antigen concentrations and prostate cancer risk, raising the possibility of diagnostic bias. By correcting for the effects of these variants on prostate specific antigen, it may be possible to create a personalized prostate specific antigen cutoff to more accurately identify individuals for whom biopsy is recommended. Therefore, we determined how many men would continue to meet common biopsy criteria after genetic correction of their measured prostate specific antigen concentrations. Materials and Methods: The genotypes of 4 single nucleotide polymorphisms previously associated with serum prostate specific antigen levels (rs2736098, rs10788160, rs11067228 and rs17632542) were determined in 964 healthy Caucasian volunteers without prostate cancer. Genetic correction of prostate specific antigen was performed by dividing an individual's prostate specific antigen value by his combined genetic risk. Analyses were used to compare the percentage of men who would meet commonly used biopsy thresholds (2.5 ng/ml or greater, or 4.0 ng/ml or greater) before and after genetic correction. Results: Genetic correction of serum prostate specific antigen results was associated with a significantly decreased percentage of men meeting biopsy thresholds. Genetic correction could lead to a 15% or 20% relative reduction in the total number of biopsies using a biopsy threshold of 2.5 ng/ml or greater, or 4.0 ng/ml or greater, respectively. In addition, genetic correction could result in an 18% to 22% reduction in the number of potentially unnecessary biopsies and a 3% decrease in potentially delayed diagnoses. Conclusions: Our results suggest that 4 single nucleotide polymorphisms can be used to adjust a man's measured prostate specific antigen concentration and potentially delay or prevent unnecessary prostate biopsies in Caucasian men.
引用
收藏
页码:1697 / 1701
页数:5
相关论文
共 50 条
  • [1] Can prostate specific antigen derivatives reduce the frequency of unnecessary prostate biopsies?
    Klein, EA
    [J]. JOURNAL OF UROLOGY, 1996, 156 (02): : 443 - 444
  • [2] Can prostate specific antigen derivatives reduce the frequency of unnecessary prostate biopsies?
    Stephan, C
    Lein, M
    Jung, K
    Schnorr, D
    Loening, SA
    [J]. JOURNAL OF UROLOGY, 1997, 157 (04): : 1371 - 1371
  • [3] REPEAT PROSTATE-SPECIFIC ANTIGEN TESTING REDUCES UNNECESSARY PROSTATE BIOPSIES
    Binette, Andrew
    Witiuk, Kelsey
    Mallick, Ranjeeta
    Morash, Chris
    Cagiannos, Ilias
    Lavallee, Luke
    Breau, Rodney
    [J]. JOURNAL OF UROLOGY, 2014, 191 (04): : E713 - E713
  • [4] PERSONALIZED PSA TESTING USING GENETIC VARIANTS CAN POSSIBLY DECREASE THE NUMBER OF PROSTATE BIOPSIES
    Helfand, Brian T.
    Loeb, Stacy
    Hofer, Matthias D.
    Kim, Dae Y.
    Hu, Qiaoyan
    Cooper, Phillip R.
    McGuire, Barry B.
    Catalona, William J.
    [J]. JOURNAL OF UROLOGY, 2012, 187 (04): : E489 - E489
  • [5] Free/total prostate-specific antigen ratio can prevent unnecessary prostate biopsies
    Trinkler, FB
    Schmid, DM
    Hauri, D
    Pei, P
    Maly, FE
    Sulser, T
    [J]. UROLOGY, 1998, 52 (03) : 479 - 486
  • [6] PROSTATE SPECIFIC ANTIGEN DENSITY CAN HELP AVOID UNNECESSARY PROSTATE BIOPSIES AT PROSTATE SPECIFIC ANTIGEN RANGE OF 4-10 ng/mL
    Lodeta, Branimir
    Benko, Goran
    Car, Sinisa
    Filipan, Zoran
    Stajcar, Damir
    Dujmovic, Tonci
    [J]. ACTA CLINICA CROATICA, 2009, 48 (02) : 153 - 155
  • [8] Combined use of prostate-specific antigen derivatives decreases the number of unnecessary biopsies to detect prostate cancer
    Özen, H
    Aygün, C
    Ergen, A
    Sözen, S
    Aki, FT
    Uygur, MC
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2001, 24 (06): : 610 - 613
  • [9] MRI-Based Radiomics Nomogram for Predicting Prostate Cancer with Gray-Zone Prostate-Specific Antigen Levels to Reduce Unnecessary Biopsies
    Zhang, Li
    Zhang, Jing
    Tang, Min
    Lei, Xiao-Yan
    Li, Long-Chao
    [J]. DIAGNOSTICS, 2022, 12 (12)
  • [10] Genetic reclassification of prostate-specific antigen levels for personalized prostate cancer screening
    Graff, Rebecca E.
    Hoffmann, Thomas J.
    Passarelli, Michael N.
    Emami, Nima C.
    Sakoda, Lori C.
    Jorgenson, Eric
    Habel, Laurel A.
    Shan, Jun
    Ranatunga, Dilrini K.
    Quesenberry, Charles P.
    Chao, Chun R.
    Ghai, Nirupa R.
    Aaronson, David
    Presti, Joseph
    Nordstrom, Tobias
    Wang, Zhaoming
    Berndt, Sonja I.
    Chanock, Stephen J.
    Mosley, Jonathan D.
    Klein, Robert J.
    Middha, Mridu
    Lilja, Hans
    Melander, Olle
    Kvale, Mark N.
    Kwok, Pui-Yan
    Schaefer, Catherine
    Risch, Neil
    Risch, Neil
    Van den Eeden, Stephen K.
    Witte, John S.
    [J]. CANCER RESEARCH, 2017, 77